Industry: Healthcare
Published Date: January-2025
Format: PPT*, PDF, EXCEL
Delivery Timelines: Contact Sales
Number of Pages: 194
Report ID: PMRREP3774
The global injectable drug delivery market is estimated to reach a size of US$ 780 Bn in 2025. It is predicted to rise at a CAGR of 8.8% through the assessment period to attain a value of US$ 1410.1 Bn by 2032.
Chronic diseases like diabetes, cancer, and autoimmune disorders, which account for over 70% of global deaths, are spurring demand for injectable drug delivery devices. The aging population, projected to reach 1.6 billion by 2050, is contributing to this demand due to their high susceptibility to chronic conditions, according to the World Health Organization (WHO).
Breakthroughs in healthcare technology, especially in injectable devices, such as wearable injectors and smart insulin pens, are enhancing patient compliance and convenience. For instance, in January 2024, the upgrade from Novo Nordisk's smart insulin pens allowed for connection with digital health systems and dosage tracking.
Government initiatives like India's Ayushman Bharat scheme and Europe's Horizon 2024 funding are promoting the use of injectables for improved healthcare access. Rising use of self-administration devices, like BD's self-injection systems, is also enhancing treatment accessibility and reducing healthcare facility dependence.
Key Highlights of the Markets
|
Market Attributes |
Key Insights |
|
Injectable Drug Delivery Market Size (2025E) |
US$ 780 Bn |
|
Projected Market Value (2032F) |
US$ 1410.1 Bn |
|
Global Market Growth Rate (CAGR 2025 to 2032) |
8.8% |
|
Historical Market Growth Rate (CAGR 2019 to 2023) |
11.2% |
North America is set to lead the global injectable drug delivery market in 2025, accounting for 40% of share. This is due to the high prevalence of chronic diseases like cardiovascular, cancer, and autoimmune disorders, necessitating unique drug delivery systems.
The U.S., with high healthcare expenditures per capita, has made investments in infrastructure, research, and pharmaceuticals, leading to the widespread adoption of injectable drug delivery systems. Prior to the patent expiration of its intravenous formulation, Merck introduced a new injectable version of Keytruda in January 2025, underscoring the market's dynamic character.
The injectable drug delivery industry in North America is set to register a CAGR of 6.9% from 2025 to 2032. It will likely be driven by the region's commitment to improving drug delivery technologies.
Europe's injectable drug delivery market, dominated by chronic diseases like diabetes and cancer among the aging population, is likely to generate 26% share in 2025. The market is projected to record a CAGR of 8.3% from 2025 to 2032. This growth is mainly supported by investments from key players in Europe. For instance,
Increasing demand for self-injectable devices, such as the BD Physioject, has led to innovations for chronic condition patients to self-administration. Because of its dynamic character, the injectable medication delivery market in Europe is anticipated to maintain its strong development trajectory in the next ten years.
Insulin pens are set to account for 53% of the injectable medication delivery industry share in 2025, making these a key segment. In addition to the convenience and ease of use that insulin pens provide to patients, this dominance can be linked to the rising incidence of insulin-dependent diabetes. For example,
Increasing number of people with diabetes and the continuous trend toward more practical and effective ways to provide insulin therapy is reflected in the fact that insulin pens have become the most popular option in the industry.
In 2025, disposable injectors are set to dominate the injectable drug delivery market with a 59% share. This is due to their single-use design, which minimizes infection risks, a critical advantage in healthcare settings.
Leading companies are bolstering disposable injector technologies to meet the growing demand for user-friendly and safe medication delivery systems in chronic diseases like diabetes and anaphylaxis. For instance,
The industry is demonstrating its commitment to innovation, focusing on improving patient adherence and outcomes through safe, effective, and convenient drug delivery solutions.
The prevalence of chronic diseases like diabetes and rheumatoid arthritis is increasing the demand for self-administered injectable medications and innovative delivery systems. The adoption of biologics and protein-based drugs requires specialized devices for precise dosing, with autoinjectors and pen injectors gaining popularity for their user-friendly designs and self-administration benefits. For instance,
Long-acting injectables, such as AstraZeneca's BYDUREON for diabetes, improve compliance by minimizing dosing frequency. BD's recyclable syringe projects in March 2023 demonstrate sustainability initiatives, while advanced coating technologies improve drug stability and delivery performance, influencing the market landscape.
The global drug delivery injection market recorded a CAGR of 11.2% in the historical period from 2019 to 2024. In the historical period, industry players stayed afloat by launching various products in the healthcare industry.
To address the rising demand for vaccinations, BD introduced BD EffivaxTM Glass prefillable syringes in 2022. BOOSTRIX was authorized by GSK to prevent pertussis in pregnant women. The first obesity drug, Zepbound injectable, was approved by the FDA for Eli & Lilly.
In the U.K. and Ireland, Novo Nordisk A/S introduced Novopen 6 and Novopen Echo Plus. The FDA approved Eli Lilly and Company's taltz injectable in 2019 for use in people with radiographic axial spondyloarthritis or active ankylosing spondylitis. Demand for injectable drug delivery systems is estimated to record a considerable CAGR of 8.8% during the forecast period between 2025 and 2032.
Rising Prevalence of Chronic Diseases to Push Demand
The need for injectable medication delivery systems has increased dramatically because of the rise in chronic illnesses worldwide, especially diabetes and autoimmune disorders. For instance,
Innovations in self-administration devices have been fueled by the increasing number of patients who need frequent injections as well as a move toward home-based treatment, which has been accelerated since the global epidemic. In response, key manufacturers have developed auto-injector designs with smart connection capabilities and better ergonomics.
Surging Emphasis on Biologics to Spur Need for Novel Methods
In order to administer biologics and protein-based medications precisely, specific injection devices are required due to the substantial changes in injectable delivery needs brought about by the biologics industry. For instance,
Specialized storage conditions and precise delivery methods are required due to the complexity of biological molecules. To preserve medication integrity, device makers have created novel materials and stabilizing techniques. Innovations in cold-chain delivery systems and intelligent temperature monitoring devices have been fueled by temperature-sensitive biologics.
Fluctuation in Prices of Raw Material and Healthcare Regulation Affects the Industry
The extensive use of injectable medication delivery devices is hampered by high production costs and strict regulatory constraints. Manufacturing costs and profit margins have been influenced by fluctuations in raw material prices. For instance,
Increased demand for specialist materials and supply chain disruptions have resulted in longer lead times and more expensive production. Issues with material availability have caused certain manufacturers to report delays in the launch of new products, which has an impact on the potential for market growth.
Development of Smart Devices for Personalized Medication Presents Prospects
The advent of digital technologies in injectable delivery systems has brought about a transformative shift in patient care and monitoring. For example,
The gadget demonstrates the revolutionary influence of digital technology on injectable delivery systems by enabling medical professionals to remotely monitor medicine adherence, modify doses, and act quickly in the event of problems.
The smart insulin pen is equipped with user-friendly features that remind patients when to take their doses and meticulously track their injection history, providing a comprehensive overview of their treatment progress.
Hospital Pharmacies to Cater to the Variety of Drug Delivery Devices
Pharmaceutical companies are projected to significantly enhance their investment in advanced research and development focused on sophisticated injectable drugs intended for use in hospital pharmacies. This strategic shift aims to improve the efficacy and accessibility of injectable drug delivery systems, which healthcare practitioners prioritize for their critical role in patient care. For example,
The continual rise in the number of hospitals, coupled with a higher influx of patients seeking treatment, further reinforces the prominence of hospital pharmacies in the healthcare sector.
Leading pharmaceutical firms are focusing progressively on extending their product lines and looking for development prospects in developing regions, particularly in the injectable drug delivery market. These companies are systematically extending their product and geographic portfolios through several acquisitions in addition to innovating by developing cutting-edge injectable drug delivery technologies.
In order to increase their market share, key firms in the market are pursuing strategic mergers and acquisitions as well as launching new drugs. Leading producers are at the forefront of technical development, creating cutting-edge products that greatly enhance the range of products available worldwide. In addition to improving patient treatment choices, this innovation increases competitiveness through synergistic benefits, putting these businesses in a position to satisfy the changing requirements of patients and healthcare providers.
Recent Industry Developments
|
Attributes |
Details |
|
Forecast Period |
2025 to 2032 |
|
Historical Data Available for |
2019 to 2023 |
|
Market Analysis |
US$ Billion for Value |
|
Key Regions Covered |
|
|
Key Market Segments Covered |
|
|
Key Companies Profiled in the Report |
|
|
Report Coverage |
|
|
Customization and Pricing |
Available upon request |
By Product
By Technology
By Usage
By Indication
By Distribution Channel
By Region
To know more about delivery timeline for this report Contact Sales
The market size is set to reach US$ 1410.1 Bn by 2032.
Intravenous (IV), intramuscular (IM), and subcutaneous (SC) are the main types.
In 2025, North America is set to attain a market share of 40%.
In 2025, the market is estimated to be valued at US$ 780 Bn.
Eli Lilly and Company, Biocon, Becton, Dickinson & Company, West Pharmaceutical Services, Inc., and Johnson & Johnson are a few key players.
